Anika Therapeutics, Inc. (ANIK) Reports Q3 EPS of 22c
Anika Therapeutics, Inc. (NASDAQ: ANIK) reported Q3 EPS of $0.22, vs. the analyst estimate of $0.11. Revenue for the quarter came in at $18.5 million versus the consensus estimate of $15.1 million.